Mironid, a biopharmaceutical company developing small-molecule therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD), raised $46 million in Series B funding. The round included new investor Scottish National Investment Bank alongside Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde. The capital will advance clinical development of Mironid’s first-in-class LoAc small-molecule candidate for ADPKD.
Advancing a New ADPKD Treatment
ADPKD is the most common hereditary kidney disorder, affecting more than 12 million people worldwide. Mironid’s LoAc molecules directly target cyclic AMP (cAMP), a pathway involved throughout ADPKD progression. Preclinical studies demonstrated reductions in cyst number and kidney volume alongside a favorable safety profile.
“ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60. Securing funding from such a high-caliber syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD. This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases,” said Neil Wilkie, CEO of Mironid.
Supporting Clinical Development
The $46 million financing will support progression of the LoAc program toward clinical development and potential treatment of rare kidney diseases.
“Our investment in Mironid reflects our commitment to backing impactful Scottish businesses with high-growth potential. Mironid exemplifies Scotland’s growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease. We are pleased to join a committed group of investors to support the company through this critical stage of development, helping it translate world-class research into clinical progress, commercial opportunity and potential patient benefit,” said Paul Callaghan, Investment Director at Scottish National Investment Bank.